221
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Multilamellar liposomes of triamcinolone acetonide: preparation, stability, and characterization

, , &
Pages 197-206 | Received 18 Nov 2008, Accepted 09 Jan 2009, Published online: 21 Aug 2009

References

  • Bangham AD, Hill MW, Miller NGA. (1974). Preparation and use of liposomes as models of biological membranes. In: Methods in Membrane Biology ( pp 1–68). New York: Korn E.D. Plenum Press.
  • Cevc G, Blume G, Schatzlein A. (1997). Transfersomers mediated. Transepidermal delivery improves the regio-specificity and biological-activity of corticosteroids in vivo. J Contr Rel 45:211–226.
  • Chiu SJ, Liu S, Perrotti D, Marcucci G, Lee RJ. (2006). Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferring receptor-targeted liposomes. J Contr Rel 112:199–207.
  • Chou HH, Wang KL, Chen CA, Wei LH, Hsieh CY, Yang YC, et al. (2006). Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol 101:423–428.
  • Clares B, Medina MM. (2007). Liposomal triamcinolone acetonide: influence of composition in performance and stability. Ars Pharm 48:19–29.
  • Doba T, Burton GW, Ingold KU. (1985). Antioxidant and coantioxidant activity of vitamin C. The effect of vitamin C, either alone or in the presence of vitamin E or a water-soluble vitamin E analogue, upon the peroxidation of aqueous multilamellar phospholipid liposomes. Biochim Biophys Acta 835:298–303.
  • Dufourc J. (1985). Physical Chemistry of Phospholipids. In: The liposomes, therapeutic applications. Paris: Technique & Documentation, pp 1–10.
  • Fesq H, Glöckner A, Abeck D, Ring J, Lehmann J, Rother M, et al. (2003). Improved risk-benefit ratio for a triamcinolone acetonide Transfersome® formulation in comparison to a commercial triamcinolone acetonide formulation. Biochim Biophysica Acta Biomembr 1614:156–164.
  • Frenkel V, Etherington A, Greene M, Quijano J, Xie J, Hunter F, et al. (2006). Delivey of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure. Acad Radiol 13:469–479.
  • Grit M, Crommelin DJA. (1993). Chemical stability of liposomes: implications for their physical stability. Chem Phys Lipids 64:3–18.
  • Guzman M, Selles E, Aberturas MR. (1989). Effect of human plasma on the stability of large multilamellar liposomes with digitoxin. Drug Dev. Ind. Pharm. 11:1759–1770.
  • Harsanyi BB, Hilchie JC, Mezei M. (1986). Liposomes as drug carriers of oral ulcers. J Dent Res 65:1.113–1.141.
  • Hayat MA. (1989). Principles and Techniques of Electron Microscopy. Biological Applications, 3rd ed ( pp 251–253). Macmillan Press.
  • Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K. (1993). Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefe’s Arch Clin Exp Ophthalmol 231:109–114.
  • Hunt CA, Tsang S. (1981). α-tocpherol retards autoxidation and prolongs the shelf life of liposomes. Int J Pharm 8:101–110.
  • Joshi MR, Misra A. (2001). Liposomal budesonide for dry powder inhaler: preparation and stabilization. Pharm Sci Tech 2:E25.
  • Korting HC, Zienicki H, Schaefer-Korting M, Braun-Falco O. (1990). Liposome encapsulation improves efficacy of betamethasone diproprionate in atopic eczema but not in psoriasis vulgaris. Eur J Clin Pharmacol 39:349–351.
  • Law SL, Huang KJ. (2001). Preparation of desmopressin-containing liposomes for intranasal delivery. J Contr Rel 70:375–382.
  • McMullen JN, Newton DW, Becker CH. (1984). Pectin-gelatin complex cohacervates. Effect of microemcapsulates sulfamerazine on size, morphology, recovery, and straction of water dispersible microglobules. J Pharm Sci 73:1799–1803.
  • Mezei M, Gulasekharam V. (1980). Liposomes, a selective drug delivery sistem for the topical route of administration. I. Lotion dosage form. Life Sci 26:1473–1477.
  • Mezei, M. (1985).. Liposomes as a Skin Drug Delivery Systems. D. D. Breimer A. In: Topics in Pharmaceutical Sciences. pp 345–358. Amsterdam P. Speiser, Eds., Elsevier Sci. Pub.
  • Nicolazzo JA, Reed BL, Finnin BC. (2005). Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide. J Contr Rel 105:240–248.
  • Pasarassi T, Giusti AM, Raimondi M, Ravagnan G, Sapora O, Gratton E. (1995). Cholesterol protects the phospholipid bilayer from oxidative damage. Free Radic Biol Med 19:511–516.
  • Puisieux F, Poly PA. (1985). Technological Problems for the use of liposomes as delivery vehicles for active ingredients, encapsulation, sterilization, preservation. In: Les liposomes, applications thérapeutiques. Paris: Technique & Documentation, pp 13–113.
  • Samuni AM, Lipman A, Barenholz Y. (2000). Damage to liposomal lipids: protection by antioxidants and cholesterol-mediated dehydration. Chem Phys Lipids 105:121–134.
  • Shaw IH, Knight CG, Dingle JT. (1976). Liposomal retention of a modified anti-inflammatory steroid. J Biochim 158:473–476.
  • Soto-Arriaza MA, Sotomayor CP, Lissi EA. (2008). Relationship bet ween lipid peroxidation and rigidity in L-α-phosphatidylcholine-DPPC vesicles. J Coll Interf Sci 23:70–74.
  • Vasson MP, Colombat A, Madelmont JC, Moreau MF, Godeneche D, Delattre J. (1981). C omparative study of encapsulation in liposomes of Nitros-urea. First European Congress of Pharmacokinetics and biopharmacy. Vol. I. Clermont-Ferrand, pp 381.
  • Vemuri S, Rhodes CT. (1995). Encapsulation of a water-soluble drug in a liposome preparation: Removal of free drug by washing. Drug Dev Ind Pharm 21:1329–1338.
  • Virtanen JA, Ruinala M, Vauhkonen M, Somerharju P. (1995). Lateral organization of liquid-crystalline colesterol-dimyristoylphosphatidylcholine bilayers. Evidence for domains with hexagonal and centered rectangular cholesterol superlattices. Biochemistry 34:11568–11581.
  • Yamabe K, Yoshinori K, Hiraku O. (2003). Potentially of double liposomes containing salmon calcitonin as an oral dosage form. J Contr Rel 89:429–436.
  • Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP. (2006). siRNA-containing liposomes modified with polyarginine silence the targeted gene. J Contr Rel 112:229–239.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.